| Market Capitalization (Millions $) |
1,984 |
| Shares
Outstanding (Millions) |
55 |
| Employees |
34 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-134 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Vera Therapeutics Inc
Vera Therapeutics Inc is a clinical-stage biotechnology company focusing on developing innovative therapies for serious unmet medical needs. The company was founded in 2019 by a team of experienced scientists and pharmaceutical professionals with extensive experience in the field of rare diseases and orphan drugs.
Vera Therapeutics is headquartered in South San Francisco, California, and has a team of over 50 employees. The company is dedicated to developing therapies for rare diseases, particularly those affecting the liver and kidneys.
The company's lead product candidate, VERA-321, is a novel treatment for primary hyperoxaluria (PH), a rare genetic disorder characterized by the overproduction of oxalate, a toxic substance that can accumulate in the kidneys and other organs, leading to severe and potentially life-threatening consequences.
VERA-321 is a small molecule inhibitor that targets the enzyme glycolate oxidase (GO), which is responsible for the synthesis of oxalate. By reducing oxalate production, VERA-321 has the potential to prevent the formation of kidney stones and other complications associated with PH.
In addition to VERA-321, Vera Therapeutics has a pipeline of other drug candidates in various stages of development, including VE-202, an inhibitor of the nuclear receptor PPAR-delta, which is being investigated for the treatment of non-alcoholic steatohepatitis (NASH), a progressive liver disease.
The company has also established partnerships with leading academic institutions and research organizations to advance its drug development programs. In 2020, Vera Therapeutics entered into a collaboration with the University of Alabama at Birmingham to study the pathophysiology of PH and identify new therapeutic targets.
Vera Therapeutics has raised over $80 million in funding to date, including a $40 million series A financing round in 2019 led by Abingworth and Amgen Ventures.
Overall, Vera Therapeutics Inc is a promising biotechnology company that is focused on developing innovative therapies for rare diseases with significant unmet medical needs. With a strong pipeline of drug candidates, a dedicated team of experts, and a commitment to advancing scientific research, Vera Therapeutics is well-positioned to make a meaningful impact in the field of rare disease therapeutics.
Company Address: 2000 Sierra Point Parkway Brisbane 94005 CA
Company Phone Number: 770-0077 Stock Exchange / Ticker: NASDAQ VERA
|
0.24% 